Growth Metrics

Merck (MRK) Gross Margin (2009 - 2026)

Merck (MRK) reported Gross Margin of 74.24% for Q1 2026, down 374.0% year-over-year from 27.1% in Q1 2025, and up 12.23% on a QoQ basis from 66.15% in Q4 2025.

Merck (MRK) has 18 years of Gross Margin data on file, last reported at 74.24% in Q1 2026.

  • Quarterly Gross Margin fell 374.0% year-over-year to 74.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 73.91% (down 251.0% YoY) and the FY2025 annual result came in at 74.8%, down 152.0% from the prior year.
  • Gross Margin advanced to 74.24% in Q1 2026 per MRK's latest filing, from 66.15% in the prior quarter.
  • Across five years, Gross Margin topped out at 77.98% in Q1 2025 and bottomed at 66.15% in Q4 2025.
  • The 5-year median for Gross Margin is 73.7% (2022), against an average of 73.79%.
  • The widest annual swing landed in 2023, when Gross Margin soared 673 bps; it then tumbled 935 bps in 2025.
  • Tracing MRK's Gross Margin over 5 years: stood at 71.94% in 2022, then climbed by 2 bps to 73.26% in 2023, then advanced by 3 bps to 75.5% in 2024, then declined by 12 bps to 66.15% in 2025, then gained by 12 bps to 74.24% in 2026.
  • Per Business Quant, the three latest MRK Gross Margin figures stand at 74.24% (Q1 2026), 66.15% (Q4 2025), and 77.69% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 81.93%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 66.31%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 71.88%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 74.24%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 68.16%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 79.24%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -51.69%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 70.22%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 74.24%
Dec 31, 2025 66.15%
Sep 30, 2025 77.69%
Jun 30, 2025 77.50%
Mar 31, 2025 77.98%
Dec 31, 2024 75.50%
Sep 30, 2024 75.51%
Jun 30, 2024 76.76%
Mar 31, 2024 77.56%
Dec 31, 2023 73.26%
Sep 30, 2023 73.29%
Jun 30, 2023 73.24%
Mar 31, 2023 72.90%
Dec 31, 2022 71.94%
Sep 30, 2022 73.70%
Jun 30, 2022 71.11%
Mar 31, 2022 66.17%
Dec 31, 2021 71.35%
Sep 30, 2021 73.77%
Jun 30, 2021 72.78%
Mar 31, 2021 69.90%
Dec 31, 2020 54.06%
Sep 30, 2020 72.43%
Jun 30, 2020 70.63%
Mar 31, 2020 72.53%
Dec 31, 2019 62.09%
Sep 30, 2019 67.81%
Jun 30, 2019 71.08%
Mar 31, 2019 71.78%
Dec 31, 2018 70.09%
Sep 30, 2018 66.47%
Jun 30, 2018 67.35%
Mar 31, 2018 68.28%
Dec 31, 2017 67.03%
Sep 30, 2017 67.97%
Jun 30, 2017 68.62%
Mar 31, 2017 67.68%
Dec 31, 2016 65.68%
Sep 30, 2016 67.64%
Jun 30, 2016 63.65%
Mar 31, 2016 61.64%
Dec 31, 2015 62.31%
Sep 30, 2015 62.66%
Jun 30, 2015 61.64%
Mar 31, 2015 62.13%
Dec 31, 2014 64.23%
Sep 30, 2014 60.00%
Jun 30, 2014 55.25%
Mar 31, 2014 61.97%
Dec 31, 2013 59.30%
Sep 30, 2013 62.80%
Jun 30, 2013 61.09%
Mar 31, 2013 62.90%
Dec 31, 2012 64.56%
Sep 30, 2012 63.99%
Jun 30, 2012 66.60%
Mar 31, 2012 65.59%
Dec 31, 2011 66.03%
Sep 30, 2011 63.80%
Jun 30, 2011 64.74%
Mar 31, 2011 64.95%
Dec 31, 2010 63.29%
Sep 30, 2010 62.33%
Jun 30, 2010 59.91%
Mar 31, 2010 54.33%
Dec 31, 2009 51.44%
Sep 30, 2009 76.36%
Jun 30, 2009 77.05%
Mar 31, 2009 75.23%